Skip to main content

Support program has roots in Basel

| News

Support program has roots in Basel

20.04.2020

The online program Selfapy supports people suffering from mental health conditions during the coronavirus lockdown. BaselArea.swiss has provided startup help by way of its DayOne initiative.

DayOne experts

The regional business promotion organization BaselArea.swiss is implementing numerous measures to support medical innovations by way of its DayOne initiative. In this context, the DayOne Experts event was held back in February, which placed the focus squarely on the issue of mental health. The participants included Professor Gunther Meinlschmidt, Research Director at the Department of Psychosomatic Medicine at the University Hospital Basel, in addition to the Berlin-based startup Selfapy. Following the event in Basel, Meinlschmidt and Selfapy have developed an online course for people suffering from mental health disorders during the COVID-19 lockdown period.

The free Selfapy program begins with an informative talk over the telephone or via email. During the online course, participants receive access to interactive exercises, videos and informative texts. A psychologist supports the participants and answers any questions they might have. In addition, the participants will be assessed personally and receive feedback on their progress.

“We followed the approach of developing a relatively broad service to offer those affected”, comments Meinlschmidt in an interview published on the website of the International Psychoanalytic University Berlin. “It consists of 12 modules into which we poured general knowledge relating to coping mechanisms and resources in the context of catastrophes and mental illnesses, all connected with specific strategies tailored to the current COVID-19 situation”, he adds. The service can be used by anyone aged 18 or over and is aimed at “people who are feeling the strain and want to do something to improve their mental health and feel less stressed during the ongoing pandemic situation.”

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

CSL joins Basel Area biotech cluster

The research and development department of the globally active Australian biotech company CSL has moved into a new office in...
Read More

Palto Therapeutics receives 150,000 Swiss francs from Venture Kick

Allschwil-based Palto Therapeutics has won the third stage of the Venture Kick promotional funding program. As such, the company now...
Read More

Beyond the cliché: the real advantages of business in Switzerland

Meet our Chief Representative USA: with over 30 years in the biotech industry, Kirsten Detrick brings invaluable expertise for companies...
Read More

Roche uses artificial intelligence for cancer diagnosis

Roche is teaming up with Ibex Medical Analytics and Amazon Web Services in the field of artificial intelligence. The goal...
Read More

Cimeio collaborating with the University of Pennsylvania

The Basel-based startup Cimeio has been offered an exceptional opportunity for a preclinical research collaboration with the University of Pennsylvania,...
Read More

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Forty51 Ventures invests to found Mysthera Therapeutics

Mysthera Therapeutics AG has been founded in Basel. Forty51 Ventures, a venture capital firm also based in Basel, has provided...
Read More

Do you have a question? We'd like to hear from you.